Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.310
-0.040 (-2.96%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Alzamend Neuro Market Cap
Alzamend Neuro has a market cap or net worth of $6.28 million as of August 3, 2026. Its market cap has decreased by -14.00% in one year.
Market Cap
6.28M
Enterprise Value
5.57M
1-Year Change
-14.00%
Ranking
Category
Stock Price
$1.31
ChartMarket Cap Chart
Since the IPO on June 15, 2021, Alzamend Neuro's market cap has decreased from $1.15B to $6.28M, a decrease of -99.45%. That is a compound annual growth rate of -63.77%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2026 | 6.28M | -9.28% |
| Dec 31, 2025 | 6.92M | 9.79% |
| Dec 31, 2024 | 6.30M | -0.56% |
| Dec 29, 2023 | 6.34M | -88.37% |
| Dec 30, 2022 | 54.47M | -67.73% |
| Dec 31, 2021 | 168.82M | -85.28% |
| Jun 15, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Can-Fite BioPharma | 6.91M |
| Imunon | 6.72M |
| AEON Biopharma | 6.71M |
| Traws Pharma | 6.68M |
| PharmaCyte Biotech | 6.44M |
| Kairos Pharma | 6.42M |
| XTL Biopharmaceuticals | 6.42M |
| Pulmatrix | 6.21M |